highli
pathogen
coronavirus
sarscov
merscov
recent
emerg
human
popul
human
coronavirus
hcov
includ
estim
circul
human
popul
hundr
year
caus
mild
respiratori
ill
approxim
common
cold
attribut
within
coronavirida
famili
order
nidoviral
four
genera
recogn
alphacoronaviru
betacoronaviru
gammacoronaviru
deltacoronaviru
six
hcov
tabl
current
identifi
belong
genera
alphacoronaviru
betacoronaviru
sarscov
merscov
gammacoronavirus
deltacoronavirus
known
virus
infect
human
contain
import
agricultur
pathogen
livestock
epizoot
coronavirus
anim
caus
wide
rang
diseas
sign
result
respiratori
enter
neurolog
tissu
tropism
although
hcov
caus
primarili
respiratori
symptom
potenti
wide
rang
sever
diseas
symptom
human
caus
infect
futur
emerg
coronavirus
exclud
despit
sever
divers
coronaviru
diseas
sign
symptom
affect
larg
number
import
livestock
speci
well
human
proven
therapi
specif
target
cov
addit
cov
known
caus
diseas
human
livestock
larg
number
highli
divers
coronavirus
identifi
base
sequenc
collect
sampl
bat
speci
bat
coronaviru
batcov
sequenc
recov
sampl
site
differ
contin
asia
europ
africa
north
america
last
decad
contain
put
batcov
divers
branch
betacoronaviru
alphacoronaviru
phylogenet
tree
importantli
two
coronavirus
caus
sever
diseas
human
sarscov
merscov
emerg
batcov
previous
recogn
infect
human
anim
bat
recent
studi
suggest
genet
similar
sarscov
enter
cell
use
human
receptor
similarli
merslik
batcov
may
also
circul
bat
popul
merslik
batcov
may
also
abl
recogn
human
host
cell
receptor
batcov
call
preemerg
may
potenti
emerg
human
popul
importantli
therapeut
reli
host
memori
respons
target
cov
infect
often
effect
preemerg
batcov
differ
antigen
known
hcov
highlight
need
pancoronaviru
therapeut
target
conserv
mechan
util
hcov
batcov
sarscov
merscov
like
evolv
batcov
infect
intermedi
host
anim
closer
proxim
human
result
sar
mer
outbreak
figur
sarscov
detect
small
anim
like
civet
raccoon
dog
present
liveanim
market
evolut
sarscov
evidenc
genom
sequenc
differ
zoonot
sarscov
strain
infect
civet
epidem
sarscov
isol
like
result
viral
adapt
thought
requir
emerg
cov
becom
transmiss
persontoperson
merscov
identifi
dromedari
camel
known
endem
camel
popul
middl
east
subsaharan
africa
research
coronavirusspecif
antivir
drug
focus
primarili
highli
pathogen
coronavirus
sarscov
merscov
due
major
potenti
consequ
pandem
result
pathogen
sarscov
merscov
transmit
effici
persontoperson
compar
respiratori
pathogen
like
season
influenza
mortal
patient
sar
approxim
mer
approxim
greatli
exceed
typic
season
influenza
casefat
rate
death
per
case
air
travel
facilit
cov
seed
outbreak
region
distant
initi
local
viral
spread
sarscov
emerg
guangdong
provinc
southeastern
china
late
spread
rapidli
part
world
outbreak
major
citi
includ
beij
hong
kong
singapor
toronto
result
one
first
pandem
twentyfirst
centuri
sinc
merscov
emerg
mer
case
export
middl
east
europ
north
america
africa
south
east
asia
includ
major
outbreak
peopl
republ
korea
superspread
individu
transmit
sarscov
merscov
larg
number
peopl
play
import
role
initi
perpetu
cov
outbreak
merscov
outbreak
republ
korea
start
singl
travel
case
five
case
respons
transmiss
event
sarscov
merscov
transmit
close
contact
known
outbreak
occur
hotel
apart
build
hospit
healthcar
center
healthcar
worker
particular
risk
infect
sarscov
merscov
high
rate
addit
anim
worker
like
come
contact
cov
infect
anim
larg
percentag
mer
patient
contact
intermedi
host
camel
analysi
sever
sar
mer
diseas
identifi
disproportion
high
casefat
rate
elderli
patient
age
year
patient
preexist
comorbid
includ
diabet
heart
diseas
hypertens
renal
diseas
base
epidemiolog
consider
pancoronaviru
therapeut
need
protect
popul
occup
risk
transmiss
cov
ii
protect
popul
suscept
sever
diseas
cov
iii
work
concert
public
health
measur
like
quarantin
contact
trace
iv
rapidli
deploy
geograph
distant
region
local
hcov
epidem
advanc
studi
highli
pathogen
coronavirus
potenti
pancoronaviru
drug
candid
partial
depend
technolog
genet
manipul
cov
probe
mechan
viral
pathogenesi
antivir
drug
activ
revers
genet
system
synthet
gener
virus
known
viral
sequenc
situat
clinic
isol
infecti
materi
unavail
due
restrict
collect
patient
sampl
ship
infecti
materi
avail
contain
laboratori
revers
genet
system
provid
essenti
research
materi
studi
viral
pathogenesi
model
develop
prior
sar
pandem
robust
revers
genet
system
manipul
genom
cov
alreadi
develop
systemat
assembl
cdna
cassett
fulllength
infecti
clone
allow
precis
target
genet
manipul
viral
gene
infecti
clone
allow
creation
nearhomogen
viral
stock
wherea
tradit
viral
stock
prepar
amplif
infecti
materi
cell
cultur
mani
passag
strategi
build
revers
genet
system
rapidli
appli
sarscov
merscov
within
first
year
identif
virus
addit
reconstruct
epidem
strain
cov
revers
genet
system
allow
target
mutat
specif
viral
gene
assembl
virus
infecti
materi
avail
exampl
abil
isol
mutat
particular
gene
appli
studi
spike
glycoprotein
sarscov
maintain
isogen
background
viral
replicas
structur
protein
mutat
zoonot
earli
middl
late
epidem
strain
sarscov
outbreak
insert
glycoprotein
epidem
strain
sarscov
urbani
determin
effect
evolut
viral
entri
human
cell
well
viral
pathogenesi
rodent
primat
model
diseas
target
mutat
specif
viral
gene
revers
genet
system
allow
research
probe
causeandeffect
relationship
host
pathogen
respons
viral
genet
chang
addit
revers
genet
techniqu
util
studi
preemerg
batcov
strain
recombin
version
sarscovlik
well
merscovlik
virus
gener
use
vitro
vivo
model
emerg
coronaviru
diseas
panel
zoonot
epidem
preemerg
virus
synthes
revers
genet
techniqu
encompass
divers
array
use
highthroughput
platform
discoveri
countermeasur
effect
broadest
rang
cov
without
reliant
procur
clinic
isol
like
virus
coronavirus
requir
host
cell
machineri
replic
genom
produc
progeni
virion
caus
diseas
cell
line
requir
express
host
cell
receptor
well
express
necessari
proteas
facilit
viral
entri
although
addit
host
factor
may
also
import
infect
glycoprotein
coronavirus
main
determin
host
cell
attach
viral
entri
well
conserv
hcov
human
coronavirus
use
differ
host
cell
receptor
viral
entri
may
also
requir
differ
host
cell
proteas
allow
fusion
viral
cellular
membran
tabl
although
known
hcov
viral
tropism
target
human
respiratori
tract
lung
cell
line
infect
broad
rang
hcov
defin
key
featur
sarscov
merscov
highli
pathogen
coronavirus
grow
higher
viral
titer
wider
rang
cell
line
mildli
pathogen
coronavirus
high
throughput
approach
screen
compound
librari
target
activ
coronavirus
underdevelop
limit
number
viral
strain
use
infect
panel
cell
line
variou
anim
speci
hcov
batcov
inform
potenti
host
rang
pathogen
may
help
identifi
suscept
mammalian
host
involv
viral
spread
howev
product
infect
cell
line
alway
translat
recapitul
pathogenesi
anim
model
cell
line
deriv
may
due
receptor
avail
live
anim
biolog
immunolog
factor
infect
infect
pseudostratifi
airway
epithelium
cultur
primari
cell
lung
provid
cell
cultur
model
simul
infect
cell
complex
environ
close
resembl
human
respiratori
tract
known
human
airway
epithelia
hae
normal
human
bronchial
epithelia
nhbe
cell
cultur
infect
hcov
identifi
thu
far
includ
sarscov
merscov
provid
potenti
platform
screen
novel
cov
emerg
human
popul
howev
sever
limit
associ
hae
includ
difficulti
collect
due
scarciti
donor
difficulti
mainten
limit
capac
cell
divis
hae
may
sourc
donor
preexist
diseas
state
could
influenc
viral
pathogenesi
addit
genet
variabl
donor
hae
cultur
often
differ
express
level
gene
crucial
infect
includ
variou
host
receptor
hcov
lead
high
variabl
infect
cultur
importantli
vitro
method
fail
captur
complex
viral
interact
occur
intact
immun
system
includ
infiltr
proinflammatori
cell
may
promot
contribut
ard
sever
form
sar
mer
organonachip
model
develop
may
provid
next
gener
vitro
model
could
captur
critic
interact
respiratori
cell
immun
cell
infect
novel
cultur
system
report
coronavirus
follow
emerg
sarscov
small
anim
model
develop
initi
inocul
anim
human
epidem
isol
sarscov
replic
mice
hamster
guinea
pig
ferret
ferret
exhibit
diseas
sign
result
infect
tabl
sarscov
replic
laboratori
strain
mice
caus
diseas
sign
viru
rapidli
clear
lung
model
serial
passag
sarscov
lung
mice
multipl
research
group
result
mouseadapt
sarscov
strain
caus
lethal
lung
diseas
wildtyp
mous
intranas
infect
model
mouseadapt
sarscov
best
character
small
anim
model
cov
infect
use
test
sever
pancoronaviru
drug
candid
benefit
mouseadapt
model
sarscov
wildtyp
inbr
mous
strain
includ
reproduc
suscept
diseas
assay
surviv
weight
loss
whole
bodi
plethysmographi
individu
mice
well
quantif
infiltr
cell
viral
titer
histopatholog
transcriptom
proteom
chang
target
organ
evalu
pathogenesi
emerg
virus
vivo
zoonot
sarscov
preemerg
batcov
mutat
incorpor
sarscov
backbon
provid
novel
anim
model
virus
potenti
emerg
human
addit
valuabl
avenu
research
variabl
known
impact
sever
cov
diseas
model
sarscov
includ
age
dose
host
genet
contribut
diseas
phenotyp
greatest
limit
sarscov
mouseadapt
model
drug
discoveri
incorpor
mutat
sarscov
genom
particularli
test
antivir
drug
target
viral
gene
mutat
acknowledg
differ
mous
human
immun
respons
unlik
sarscov
human
clinic
strain
merscov
tabl
replic
mice
hamster
ferret
studi
host
receptor
identifi
critic
amino
acid
residu
differ
merscov
receptor
laboratori
anim
model
speci
prevent
entri
cell
compar
human
merscov
infect
rabbit
result
viral
replic
upper
respiratori
tract
clinic
diseas
sign
reflect
sever
merscov
diseas
symptom
report
although
model
use
limit
test
merscov
antivir
therapeut
howev
due
util
mouseadapt
sarscov
model
mous
model
continu
pursu
adenovirusvector
transient
express
human
receptor
mice
subsequ
replic
merscov
mice
determin
merscov
replic
depend
human
express
rodent
transgen
express
human
mice
allow
merscov
replic
mice
result
lethal
brain
diseas
repres
merscov
infect
human
replac
mous
express
human
mice
result
human
mous
model
allow
merscov
replic
within
lung
mersassoci
lung
patholog
lethal
diseas
similarli
knockin
express
human
exon
mice
allow
viral
replic
overt
mer
diseas
sign
serial
passag
merscov
lung
mice
result
mersma
viru
caus
lethal
diseas
mice
includ
weight
loss
sever
lung
patholog
identif
amino
acid
mous
prevent
entri
merscov
mous
cell
led
ration
design
mous
gene
edit
express
two
human
mutat
mice
support
viral
replic
without
sever
diseas
lethal
serial
passag
merscov
gener
mouseadapt
viru
call
produc
lethal
diseas
mice
although
mani
metric
diseas
avail
mersma
model
drug
discoveri
coronaviru
antivir
addit
drawback
requir
mouseadapt
viru
modifi
rodent
host
despit
limit
mous
model
adapt
sarscov
merscov
current
bestdevelop
model
highli
pathogen
coronaviru
infect
avail
pancoronaviru
drug
discoveri
small
anim
model
thoroughli
develop
model
sarscov
merscov
infect
due
eas
manipul
rodent
increas
cost
ethic
concern
associ
nonhuman
primat
nhp
howev
nhp
model
develop
highli
pathogen
coronaviru
infect
pivot
evalu
pancoronaviru
therapeut
host
immun
respons
nhp
share
greater
homolog
human
compar
rodent
may
accur
indic
immunolog
biomark
sever
diseas
need
evalu
pancoronaviru
therapeut
diseas
sign
observ
nhp
model
infect
without
adapt
cov
requir
rodent
model
sarscov
merscov
sarscov
merscov
isol
human
replic
nhp
indic
conserv
import
aspect
coronavirusinduc
diseas
includ
respiratori
tract
biolog
receptor
homolog
pattern
express
host
receptor
proteas
sarscov
infect
common
laboratori
primat
speci
rout
includ
african
green
monkey
rhesu
macaqu
cynomolgu
macaqu
common
marmoset
result
diseas
sign
differ
degre
sever
none
reflect
lethal
sar
diseas
seen
human
tabl
commonli
report
diseas
sign
includ
lethargi
increas
respiratori
rate
follow
sarscov
infect
multipl
nhp
model
infect
acut
sign
ill
includ
fever
dyspnea
infrequ
report
sever
diseas
phenotyp
observ
histopatholog
lung
acut
time
postinfect
day
typic
find
pulmonari
lesion
pneumon
occasion
observ
diffus
alveolar
damag
although
none
nhp
speci
infect
sarscov
develop
lethal
respiratori
diseas
reflect
sar
patient
nhp
model
recapitul
enhanc
diseas
age
nhp
includ
aberr
innat
immun
signal
program
howev
lack
emul
human
sar
diseas
never
resolv
nhp
model
could
use
consist
evalu
therapeut
candid
sarscov
merscov
infect
nonhuman
primat
model
report
best
character
nhp
model
merscov
infect
rhesu
macaqu
common
marmoset
tabl
administ
merscov
via
rout
either
rhesu
macaqu
common
marmoset
result
mild
diseas
observ
diseas
phenotyp
howev
infect
rhesu
macaqu
common
marmoset
multipl
concurr
rout
oral
ocular
result
moder
diseas
rhesu
macaqu
sever
diseas
marmoset
infect
nhp
multipl
rout
like
caus
system
infect
potenti
repres
human
merscov
infect
although
marmoset
current
best
develop
nhp
model
merscov
diseas
discrep
diseas
sever
marmoset
infect
multipl
rout
marmoset
infect
rout
illumin
potenti
difficulti
use
model
drug
develop
studi
small
size
fragil
marmoset
preclud
serial
blood
draw
multipl
day
follow
infect
may
confound
experiment
outcom
result
merscov
infect
treatment
absenc
reproduc
clinic
diseas
sign
like
fever
respiratori
distress
lethal
recapitul
human
symptom
sar
mer
indic
current
develop
model
present
signific
challeng
test
pancoronaviru
antivir
nhp
model
infect
small
molecul
nucleosid
analog
demonstr
antivir
activ
vitro
sever
viral
famili
emerg
infecti
diseas
includ
filovirida
pneumovirida
paramyxovirida
coronavirida
efficaci
postexposur
treatment
ebola
virusinfect
nonhuman
primat
led
inclus
experiment
therapi
infant
survivor
ebola
viru
diseas
encourag
result
demonstr
may
accept
therapeut
intervent
lethal
viral
diseas
even
day
viral
exposur
toler
patient
viral
diseas
previous
treat
primarili
support
care
base
activ
merscov
within
larger
panel
target
lethal
virus
multipl
viral
famili
addit
studi
demonstr
decreas
viral
titer
viral
rna
vitro
model
sarscov
merscov
infect
hae
addit
similar
effect
divers
cov
includ
mous
hepat
viru
mhv
betacoronaviru
group
importantli
inhibit
replic
preemerg
batcov
includ
activ
vivo
cov
support
amelior
diseas
sign
weight
loss
lung
viral
titer
sarscov
infect
mice
treat
prophylact
therapeut
although
viral
resist
shown
experiment
vitro
mutat
conserv
motif
sarscov
mhv
result
decreas
viral
fit
vitro
vivo
altogeth
vitro
vivo
data
support
develop
potenti
pancoronaviru
antivir
base
result
sever
cov
includ
highli
pathogen
cov
potenti
emerg
batcov
initi
develop
proteas
inhibitor
vitro
activ
also
target
sarscov
nonstructur
protein
sarscov
epidem
combin
therapi
ribavirin
sar
patient
associ
decreas
viral
load
decreas
advers
clinic
outcom
death
ard
compar
histor
control
case
shortli
emerg
mer
high
throughput
screen
approach
known
antivir
compound
identifi
lopinavir
activ
merscov
vitro
oral
treatment
lopinavirritonavir
marmoset
model
merscov
infect
result
modest
improv
mer
diseas
sign
includ
decreas
pulmonari
infiltr
identifi
chest
xray
decreas
interstiti
pneumonia
decreas
weight
loss
mer
patient
case
report
treatment
regimen
includ
lopinavirritonavir
associ
posit
diseas
outcom
includ
defervesc
viral
clearanc
serum
sputum
surviv
base
vitro
vivo
activ
merscov
clinic
trial
design
use
combin
lopinavirritonavir
therapi
hospit
mer
patient
saudi
arabia
ribavirin
guanosin
analog
vitro
activ
larg
number
highli
lethal
emerg
virus
mechanist
ribavirin
inhibit
rna
synthesi
viral
rdrp
well
inhibit
mrna
cap
howev
studi
demonstr
sarscov
merscov
sensit
ribavirin
vitro
dose
significantli
inhibit
cov
replic
exceed
ribavirin
concentr
attain
typic
human
regimen
recent
demonstr
excis
ribavirin
nucleosid
analog
conserv
coronaviru
proofread
mechan
like
account
decreas
vitro
efficaci
ribavirin
expect
addit
vivo
test
ribavirin
mous
model
found
limit
activ
sarscov
ribavirin
alon
suggest
ribavirin
treatment
enhanc
sar
diseas
sign
howev
combin
treatment
ribavirin
type
interferon
primat
model
improv
mer
diseas
sign
ribavirin
given
part
treatment
regimen
sar
mer
patient
metaanalys
case
studi
found
limit
efficaci
ribavirin
treat
patient
highli
pathogen
coronaviru
respiratori
syndrom
monoclon
antibodi
mab
potenti
util
combat
highli
pathogen
viral
diseas
prophylact
therapeut
neutral
structur
protein
virion
vitro
vivo
approach
multipl
group
identifi
mab
target
either
sarscov
merscov
inhibit
viral
replic
amelior
sar
mer
diseas
anim
model
exampl
antibodi
gener
glycoprotein
merscov
inhibit
viral
replic
administ
h
prior
infect
well
h
postinfect
human
mous
model
gener
mab
effect
cov
infect
anim
model
target
highli
variabl
glycoprotein
mab
lack
crossprotect
relat
cov
monoclon
antibodi
develop
sarscov
merscov
emerg
cov
may
requir
separ
formul
viru
due
differ
target
antigen
exampl
mab
target
sarscov
isol
fail
neutral
close
relat
mab
neutral
gener
mab
target
specif
epitop
virus
avoid
neutral
accru
mutat
target
epitop
allow
viral
escap
mab
therapi
preclin
clinic
mab
formul
may
includ
cocktail
multipl
mab
target
differ
epitop
ensur
virus
escap
neutral
howev
sarscov
toler
mutat
multipl
epitop
allow
escap
neutral
multipl
mab
introduct
mab
escap
mutat
enhanc
pathogenesi
viru
anim
model
sum
efficaci
monoclon
antibodi
therapi
highli
pathogen
coronavirus
may
requir
sever
mab
target
conserv
epitop
rigor
test
requir
demonstr
viral
evas
mab
result
enhanc
virul
vaccin
long
consid
gold
standard
infecti
diseas
prevent
erad
target
human
popul
well
confer
benefit
longliv
immun
protect
individu
zoonot
pathogen
like
coronavirus
emerg
anim
reservoir
speci
thu
vaccin
strategi
unlik
lead
erad
viru
continu
circul
reservoir
host
one
health
approach
solv
problem
emerg
infecti
diseas
consid
environ
anim
health
well
human
health
exampl
vaccin
strategi
target
camel
intermedi
host
merscov
develop
may
work
repress
viral
replic
camel
prevent
merscov
transmiss
human
human
infect
highli
pathogen
coronavirus
sarscov
merscov
vulner
popul
patient
age
patient
comorbid
design
efficaci
vaccin
patient
group
difficult
vaccin
formul
develop
sarscov
fail
protect
anim
model
age
popul
also
result
immunopatholog
younger
popul
sar
diseas
enhanc
vaccin
group
subsequ
challeng
sarscov
addit
vaccin
gener
memori
immun
respons
specif
pathogen
vaccin
formul
develop
effect
multipl
cov
due
divers
batcov
seem
unlik
current
therapeut
strategi
target
specif
sarscov
merscov
antigen
efficaci
futur
coronavirus
emerg
human
popul
vaccin
formul
sarscov
epidem
antigen
offer
effect
protect
sarslik
batcov
current
circul
bat
popul
rather
modular
vaccin
platform
rapidli
adjust
newli
emerg
viral
antigen
potenti
pandem
cov
may
abl
provid
emerg
vaccin
coverag
emerg
viral
strain
antivir
compound
specif
target
viral
protein
may
result
viral
escap
mutat
target
viral
protein
describ
monoclon
antibodi
howev
target
conserv
host
mechan
util
multipl
coronaviru
essenti
part
viral
life
cycl
approach
pancoronaviru
drug
develop
viral
escap
mutat
less
like
sever
group
attempt
inhibit
host
proteas
includ
furin
cathepsin
process
viral
glycoprotein
cell
surfac
viral
entri
howev
due
variat
viral
glycoprotein
among
differ
cov
variat
host
proteas
requir
viral
entri
tabl
combin
proteas
inhibitor
would
requir
pancoronaviru
treatment
regimen
particularli
emerg
novel
cov
host
proteas
requir
evalu
addit
host
target
less
establish
mechan
activ
includ
cyclosporin
class
cyclophilin
inhibitor
antivir
activ
coronavirus
addit
immunosuppress
properti
nonimmunosuppress
deriv
cyclosporin
like
alisporivir
retain
antivir
properti
vitro
coronavirus
includ
sarscov
merscov
effect
sarscov
mous
model
infect
interferon
ifn
class
immunomodulatori
compound
produc
host
cell
respons
detect
pathogenspecif
motif
result
ifn
secret
affect
stimul
cell
also
neighbor
cell
earli
infect
ifn
stimul
result
alter
cellular
transcript
program
lead
antivir
state
character
activ
larg
set
host
gene
partial
defin
antivir
function
base
potenti
benefici
immunomodulatori
properti
context
infect
ifn
use
treatment
emerg
viral
infect
specif
antivir
drug
yet
exist
greatest
benefit
result
administr
earli
follow
infect
sarscov
merscov
type
ifn
effect
decreas
viral
replic
vitro
show
addit
benefit
vivo
primat
model
infect
ifn
use
treatment
sar
mer
patient
often
occur
combinatori
therapi
drug
includ
ribavirin
lopinavirritonavir
although
potenti
benefici
effect
therapi
limit
potenti
due
administr
later
time
postinfect
upstream
stimul
ifn
induct
includ
polyi
c
result
ifn
signal
cascad
activ
demonstr
effect
vitro
vivo
sarscov
merscov
addit
immunomodulatori
compound
regul
express
innat
immun
gene
suggest
potenti
therapeut
highli
pathogen
coronavirus
howev
compound
modul
host
respons
requir
signific
test
rigor
anim
model
therapeut
applic
could
pursu
exampl
corticosteroid
methylprednisolon
given
treatment
sar
mer
epidem
due
immunomodulatori
effect
suppress
inflammatori
respons
perceiv
benefit
possibl
deleteri
effect
respons
outbreak
previous
unrecogn
respiratori
syndrom
character
atyp
pneumonia
collabor
new
research
program
quickli
establish
identifi
etiolog
agent
involv
highli
pathogen
coronavirus
sarscov
merscov
coronavirus
may
potenti
caus
devast
pandem
due
uniqu
featur
viru
biolog
includ
rapid
viral
replic
broad
host
rang
crossspeci
transmiss
persontoperson
transmiss
lack
herd
immun
human
popul
sarscov
merscov
contain
dilig
enforc
public
health
measur
limit
viral
spread
approxim
case
total
sar
mer
sinc
howev
threat
sarscov
merscov
asyet
unknown
batcov
caus
sever
diseas
human
make
antivir
therapeut
broadli
target
coronavirus
highli
desir
commod
ensur
global
public
health
current
challeng
produc
medic
countermeasur
protect
vulner
popul
known
coronavirus
like
sarscov
merscov
also
effect
novel
highli
pathogen
coronavirus
may
emerg
anim
reservoir
host
sarscov
merscov
rapidli
identifi
follow
clinic
report
novel
atyp
pneumonia
progress
develop
effect
antivir
sarscov
merscov
imped
sever
factor
key
find
review
literatur
current
anim
model
highli
pathogen
coronavirus
sarscov
merscov
adequ
support
advanc
develop
antivir
therapeut
merscov
continu
circul
arabian
peninsula
provid
opportun
investig
treatment
mer
clinic
trial
howev
futur
emerg
coronavirus
may
requir
use
fda
anim
efficaci
rule
investig
new
drug
ind
ind
must
fulfil
anim
efficaci
rule
criteria
reason
safeti
initi
use
human
ii
pharmacolog
data
support
reason
wellunderstood
mechan
activ
pathogen
iii
efficaci
anim
model
diseas
sign
repres
clinic
ill
human
includ
one
nonrod
model
vigor
pursuit
small
anim
model
success
gener
rodent
model
recapitul
sever
sar
mer
diseas
sign
includ
morbid
mortal
progress
gener
addit
anim
model
lag
particularli
primat
model
sarscov
merscov
infect
past
strategi
experiment
treatment
regimen
primarili
reli
combin
therapi
approv
drug
known
accept
safeti
profil
broadspectrum
antivir
activ
includ
ifn
ribavirin
corticosteroid
howev
analys
data
return
treatment
indic
regimen
effect
treat
sar
mer
patient
suffici
invest
develop
drug
discoveri
pipelin
model
system
pancoronaviru
target
base
support
vitro
vivo
evid
effect
treatment
current
mer
outbreak
futur
outbreak
emerg
cov
figur
addit
logist
challeng
drug
develop
hinder
discoveri
pancoronaviru
therapeut
avail
divers
coronaviru
clinic
isol
build
vitro
vivo
system
drug
discoveri
limit
emphasi
discoveri
coronaviru
antivir
target
toward
genu
betacoronaviru
includ
sarscov
merscov
howev
therapeut
target
known
coronaviru
threat
public
health
paramount
import
critic
note
futur
outbreak
emerg
highli
pathogen
coronavirus
human
could
result
coronaviru
genera
uniqu
tropism
differ
tissu
differ
clinic
sign
symptom
alter
transmiss
profil
captur
limit
drug
discoveri
studi
viral
strain
sarscov
merscov
current
avail
research
current
biodefens
emerg
infect
research
resourc
repositori
bei
resourc
sourc
limit
number
strain
sarscov
merscov
laboratori
strain
avail
american
type
cultur
collect
strain
avail
either
resourc
high
throughput
surrog
system
biosafeti
level
welldevelop
yet
captur
phylogenet
divers
within
famili
coronavirida
biosafeti
level
condit
requir
work
sarscov
merscov
preemerg
zoonot
strain
due
sever
diseas
virus
caus
restrict
number
laboratori
safe
perform
screen
pancoronaviru
therapeut
last
year
two
outbreak
previous
unknown
highli
pathogen
coronavirus
sarscov
merscov
demonstr
cov
continu
spill
human
popul
like
facilit
interact
infect
anim
human
revers
genet
approach
gener
preemerg
batcov
sequenc
especi
relat
sarscov
merscov
particularli
novel
avenu
research
identifi
batcov
strain
similar
pathogen
profil
sarscov
merscov
continu
circul
within
bat
popul
indic
continu
vulner
highli
pathogen
coronaviru
emerg
next
emerg
coronaviru
may
symptomat
antigen
similar
sarscov
merscov
possibl
exist
novel
highli
pathogen
coronavirus
may
pois
spillov
human
popul
potenti
disastr
consequ
current
public
health
measur
adequ
stymi
spread
sarscov
merscov
primarili
due
diseas
surveil
coupl
virus
limit
persontoperson
transmiss
howev
biolog
factor
increas
crossspeci
transmiss
facilit
persontoperson
spread
may
lead
futur
coronaviru
strain
capabl
contain
time
quarantin
infect
individu
increas
highli
pathogen
cov
virul
pathogenesi
transmiss
would
like
requir
target
medic
countermeasur
without
strateg
research
program
fill
gap
identifi
literatur
review
medic
countermeasur
target
highli
pathogen
coronavirus
brought
market
leav
global
public
health
vulner
emerg
threat
